CN110917391A - Polypeptide modified sodium alginate/PVA hydrogel dressing and preparation method thereof - Google Patents
Polypeptide modified sodium alginate/PVA hydrogel dressing and preparation method thereof Download PDFInfo
- Publication number
- CN110917391A CN110917391A CN201911362307.5A CN201911362307A CN110917391A CN 110917391 A CN110917391 A CN 110917391A CN 201911362307 A CN201911362307 A CN 201911362307A CN 110917391 A CN110917391 A CN 110917391A
- Authority
- CN
- China
- Prior art keywords
- sodium alginate
- polypeptide
- parts
- hydrogel dressing
- pva hydrogel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical class CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 title claims abstract description 52
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 40
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 40
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 40
- 239000000017 hydrogel Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 39
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 39
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 11
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 238000004132 cross linking Methods 0.000 claims abstract description 4
- 239000008213 purified water Substances 0.000 claims abstract description 4
- 239000001110 calcium chloride Substances 0.000 claims abstract description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 3
- 150000002500 ions Chemical class 0.000 claims abstract description 3
- 239000000661 sodium alginate Substances 0.000 claims description 27
- 235000010413 sodium alginate Nutrition 0.000 claims description 25
- 229940005550 sodium alginate Drugs 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 15
- 239000000499 gel Substances 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 6
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 4
- 108010039918 Polylysine Proteins 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000010257 thawing Methods 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 abstract description 10
- 208000027418 Wounds and injury Diseases 0.000 abstract description 10
- 230000001684 chronic effect Effects 0.000 abstract description 5
- 230000029663 wound healing Effects 0.000 abstract description 5
- 230000023597 hemostasis Effects 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 239000000227 bioadhesive Substances 0.000 abstract description 2
- 230000003115 biocidal effect Effects 0.000 abstract description 2
- 210000000416 exudates and transudate Anatomy 0.000 abstract description 2
- 230000014759 maintenance of location Effects 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 8
- 239000004744 fabric Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000007227 biological adhesion Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000002464 physical blending Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a polypeptide modified sodium alginate/PVA hydrogel dressing and a preparation method thereof, wherein the dressing comprises the following components in parts by weight: 1-3 parts of sodium alginate derivative, 6-9 parts of polyvinyl alcohol, 5-10 parts of glycerol, 0.1-5 parts of calcium chloride and 73-88 parts of purified water. The polypeptide modified sodium alginate/PVA double-network interpenetrating hydrogel dressing suitable for chronic wound care is prepared by blending the polypeptide modified sodium alginate and a PVA solution and combining a repeated freeze-thaw method and an ion crosslinking method, and has the functions of bioadhesive hemostasis, broad-spectrum antibiosis, wound exudate absorption, moisture retention and wound healing promotion.
Description
Technical Field
The invention relates to the technical field of medical dressing preparation, in particular to a polypeptide modified sodium alginate/PVA hydrogel dressing and a preparation method thereof.
Background
With the continuous rise of the living standard of human beings and the development of aging population, the prevalence rate of diabetes at home and abroad is increased year by year, the diabetic foot is a common complication of a diabetic patient, a wound is difficult to heal and easy to infect, amputation or death can be caused seriously, great inconvenience and pain are brought to the life of the patient, and the development of the hydrogel wound dressing suitable for chronic wound care is an effective way for relieving the pain of the patient.
The hydrogel is a polymer which has a three-dimensional network structure and is insoluble and capable of swelling in water and retaining a large amount of water, and is formed by mutual crosslinking through covalent bonds, hydrogen bonds or van der waals forces. The hydrogel contains a large amount of water, is similar to human tissues, has excellent biocompatibility, and is widely applied to the field of medical dressings. The polyvinyl alcohol is safe and nontoxic, and in the process of forming gel, the hydrogen bond of hydroxyl groups among polyvinyl alcohol molecular chains can form a winding structure, so that the gel has excellent mechanical properties. The polyvinyl alcohol and the alginate are combined to prepare the hydrogel, so that the hydrogel has the effects of moisturizing and promoting wound healing. The natural polypeptide and the tissue have ionic electrostatic interaction and good tissue adhesion, and the biological adhesion of the gel can be enhanced and the broad-spectrum bacteriostasis effect can be achieved by introducing the natural polypeptide and the tissue into a gel system in a physical blending or grafting manner.
Disclosure of Invention
The invention aims to provide a polypeptide modified sodium alginate/PVA hydrogel dressing suitable for chronic wound care, which is applied to chronic wound care, more effectively prevents wound infection and promotes wound healing.
In order to solve the technical problems, the invention provides the following technical scheme: the paint comprises the following components in parts by weight: 1-3 parts of sodium alginate derivative, 6-9 parts of polyvinyl alcohol, 5-10 parts of glycerol, 0.1-5 parts of calcium chloride and 73-88 parts of purified water.
The preparation method of the polypeptide modified sodium alginate/PVA hydrogel dressing comprises the following steps:
s1: dispersing a certain amount of sodium alginate polypeptide derivative in glycerol, adding deionized water, and stirring for dissolving uniformly.
S2, preparing a polyvinyl alcohol aqueous solution, dissolving in a water bath at 85 ℃, mixing with S1, pouring into a mold, and repeatedly freezing and thawing for three times.
S3: and (4) soaking the gel obtained in the step (S2) in a calcium chloride solution, and then washing, drying, cutting, packaging and sterilizing to obtain the double-network interpenetrating sodium alginate polypeptide derivative/PVA hydrogel dressing.
The preparation method of the sodium alginate polypeptide derivative comprises the following steps:
s1: sodium alginate was dissolved in 2- (N-morpholino) ethanesulfonic acid (MES) buffer solution, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide were added thereto and stirred at room temperature for 18 hours.
And S2, adding epsilon-polylysine, continuing stirring for 2 hours, dialyzing for 3 days, and freeze-drying to obtain the sodium alginate polypeptide derivative.
The invention has the beneficial effects that:
(1) the polypeptide modified sodium alginate/PVA hydrogel dressing dual-network interpenetrating gel dressing prepared by the method has stable performance and can be stored at normal temperature.
(2) The polypeptide modified sodium alginate/PVA hydrogel dressing has the advantages that the polypeptide is introduced through chemical grafting, the biological adhesiveness of the gel is enhanced, the bacterial growth is inhibited, the wound is adhered, and the hemostasis is accelerated.
(3) The alginate used as the raw material of the polypeptide modified sodium alginate/PVA hydrogel dressing has good biocompatibility, has the effect of promoting wound healing and has good biocompatibility.
(4) The polypeptide modified sodium alginate/PVA double-network interpenetrating hydrogel dressing suitable for chronic wound care is prepared by blending the polypeptide modified sodium alginate and a PVA solution and combining a repeated freeze-thaw method and an ion crosslinking method, and has the functions of bioadhesive hemostasis, broad-spectrum antibiosis, wound exudate absorption, moisture retention and wound healing promotion.
Drawings
FIG. 1 is a comparison graph of bacteriostatic test results.
Detailed Description
The first embodiment is as follows:
a preparation method of a polypeptide modified sodium alginate/PVA hydrogel dressing comprises the following steps:
s1: weighing 2.0g of sodium alginate polypeptide derivative, dispersing in 5mL of glycerol, adding 30mL of deionized water, and stirring uniformly to prepare a sodium alginate polypeptide derivative solution with a certain concentration.
S2, 8.0g of polyvinyl alcohol is weighed, 70mL of distilled water is added, and the mixture is dissolved uniformly in a water bath at 85 ℃. At room temperature, the sodium alginate polypeptide derivative solution and the polyvinyl alcohol solution are mixed evenly and poured into a mould. The mixture was then frozen in a refrigerator for 6 hours and thawed at room temperature for 2 hours, repeated three times.
S3: and (3) soaking the gel obtained in the step (S2) in a calcium chloride solution, and then washing, drying, cutting, packaging and completely killing to obtain the double-network interpenetrating sodium alginate polypeptide derivative/PVA hydrogel dressing.
Example two:
a preparation method of a polypeptide modified sodium alginate/PVA hydrogel dressing comprises the following steps:
s1: 3.0g of sodium alginate polypeptide derivative is weighed and dispersed in 5mL of glycerol, 30mL of deionized water is added and stirred uniformly, and sodium alginate polypeptide derivative solution with certain concentration is prepared.
S2, weighing 7.0g of polyvinyl alcohol, adding 70mL of distilled water, and dissolving uniformly in a water bath at 85 ℃. At room temperature, the sodium alginate polypeptide derivative solution and the polyvinyl alcohol solution are mixed evenly, poured into a mold, then placed into a refrigerator for freezing for 8 hours, unfrozen at room temperature for 3 hours, and repeated for three times.
S3: and (3) soaking the gel obtained in the step (S2) in a calcium chloride solution, and then washing, drying, cutting, packaging and completely killing to obtain the double-network interpenetrating sodium alginate polypeptide derivative/PVA hydrogel dressing.
Example three:
the preparation method of the sodium alginate polypeptide derivative comprises the following steps:
s1: preparing 100mL of 2- (N-morpholino) ethanesulfonic acid (MES) buffer solution with the concentration of 0.25mol/L, dropwise adding sodium chloride solution to adjust the pH value to 6.5, adding 1.0g of sodium alginate, and stirring until the sodium alginate is fully dissolved.
S2 adding 0.70g of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDC) and 0.26g of N-hydroxysuccinimide, stirring at normal temperature for 18 hours, adding epsilon-polylysine, continuing stirring for 2 hours, dialyzing with purified water for three days, and freeze-drying to obtain the sodium alginate polypeptide derivative.
Example four:
prepared by the invention
Sodium alginate derivatives and
the hydrogel dressings were separately subjected to in vitro cytotoxicity tests.
Reference is made to GB/T16886.5-2017 medical device biology evaluation part five: in vitro cytotoxicity assay methods.
Cell line: mouse fibroblast L929
Negative control group: 2% fetal bovine serum culture medium
Positive control group: 10% DMSO solution
Test groups: adding 2 percent fetal calf serum culture medium leaching liquor according to the proportion of 0.1g/ml of the sample mass, and shaking at the constant temperature of 37 ℃ for 24 +/-1 h.
Digesting cultured cells with vigorous growth for 48-72 h to obtain the cell with density of 1.5 × 104Inoculating the cell suspension of each cell/ml into a 96-well plate, adding 100 mu L of the cell suspension into each well, and placing the cell suspension in 5% CO2The culture was carried out in an incubator at 37 ℃ for 24 hours.
Discarding the original culture solution, adding 200 μ L negative control solution, positive control solution, and sample solution, placing 5 holes in each group, and placing in 5% CO2The culture was carried out in an incubator at 37 ℃ for 48 hours. Adding 15 mu LMTT solution and 5% CO into each hole2Culturing for 4h at 37 ℃ in an incubator, discarding the culture solution, adding 150 mu LDMSO respectively, shaking for 10min, detecting the absorbance at 490nm on an enzyme-labeling instrument, calculating the increment rate, and grading the in-vitro cytotoxicity reaction according to the table 1. The test results are shown in table 2.
TABLE 1 in vitro cytotoxicity response ranking
| Toxicity rating (grade) | 0 | 1 | 2 | 3 | 4 |
| Relative proliferation Rate (%) | ≥100 | 80-99 | 50-79 | 30-49 | 0-29 |
TABLE 2 in vitro cytotoxicity test results
| Sample (I) | 2D |
|
|
Level 1 |
|
|
Level 1 |
| Positive control | 4 stage |
As can be seen from Table 3, will
Sodium alginate derivatives and
the leaching liquor of the hydrogel dressing is used for culturing cells for 2 days respectively, and the cytotoxicity reaction grading is 1 grade, which shows that the sodium alginate derivative and the hydrogel dressing both have good biocompatibility.
Example five:
the polypeptide modified sodium alginate/PVA hydrogel dressing prepared by the invention is subjected to a bacteriostasis test.
The quantitative bacteriostasis test is carried out according to the carrier soaking method specified in WS/T650-2019.
Washing 24h fresh slant culture of test bacterium Escherichia coli with PBS, and diluting to 5.0 × 106CFU/mL～5.0×107CFU/mL bacterial suspension is ready for use. 10 mul of the bacterial suspension was applied by drop-dyeing to sterilized plain cloth pieces (10 mm. times.10 mm) and dried at 36 ℃. + -. 1 ℃ for use.
Weighing a sample according to the amount of 5 g/piece, placing the sample in a sterile plate, placing the sterile plate in a water bath at 20 +/-1 ℃ for 5min, taking a bacteria-staining cloth piece by using a sterile forceps, completely immersing the cloth piece in the sample, immediately timing, respectively taking out the bacteria-staining cloth piece, placing the bacteria-staining cloth piece into 5.0 mL PBS test tubes after 6 hours of interaction between a bacteria-staining carrier and the sample, uniformly mixing, oscillating, washing test bacteria, respectively absorbing 1.0 mL sample liquid, determining the number of viable bacteria according to a viable bacteria culture counting method, and inoculating 2 plates in each tube of sample liquid. The same batch of PBS was taken as negative control. All test samples and control samples were incubated at 36 ℃. + -. 1 ℃ for 48h to observe the results. The experiment was repeated 3 times, and the inhibition rate was calculated, and the experimental results are shown in fig. 1.
As can be seen from FIG. 1, compared with the blank group, the polypeptide-modified sodium alginate/PVA hydrogel dressing prepared by the invention has antibacterial activity, and the average antibacterial rate is 79.9%.
While specific embodiments of the present invention have been described above, the present invention is not limited to the above embodiments, and various modifications can be made within the scope of the technical gist of the present invention in the technical field of the present invention, as long as the general knowledge is grasped.
Claims (5)
1. The polypeptide modified sodium alginate/PVA hydrogel dressing is characterized by comprising the following components in parts by weight: 1-3 parts of sodium alginate derivative, 6-9 parts of polyvinyl alcohol, 5-10 parts of glycerol, 0.1-5 parts of calcium chloride and 73-88 parts of purified water.
2. The polypeptide-modified sodium alginate/PVA hydrogel dressing as claimed in claim 1, wherein the polypeptide-modified sodium alginate/PVA hydrogel dressing is prepared by mixing a sodium alginate polypeptide derivative with polyvinyl alcohol, and combining a repeated freeze-thaw method and an ion crosslinking method.
3. The polypeptide-modified sodium alginate/PVA hydrogel dressing as claimed in claim 2, wherein the sodium alginate polypeptide derivative is obtained by grafting sodium alginate with epsilon-polylysine.
4. The polypeptide-modified sodium alginate/PVA hydrogel dressing as claimed in claim 3, wherein the preparation method of the sodium alginate polypeptide derivative comprises the following steps:
s1: dissolving sodium alginate in 2- (N-morpholino) ethanesulfonic acid buffer solution, adding 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide, and stirring at normal temperature for 18 hours;
and S2, adding epsilon-polylysine, continuing stirring for 2 hours, dialyzing for 3 days, and freeze-drying to obtain the sodium alginate polypeptide derivative.
5. The preparation method of the polypeptide-modified sodium alginate/PVA hydrogel dressing as claimed in any one of claims 1 to 4, characterized by comprising the following steps:
s1: dispersing a certain amount of sodium alginate polypeptide derivative in glycerol, adding deionized water, and stirring for dissolving uniformly;
s2, preparing a polyvinyl alcohol aqueous solution, dissolving in a water bath at 85 ℃, blending with S1, pouring into a mold, and repeatedly freezing and thawing for three times to obtain gel;
s3: and (4) soaking the gel obtained in the step (S2) in a calcium chloride solution, and then washing, drying, cutting, packaging and sterilizing to obtain the double-network interpenetrating sodium alginate polypeptide derivative/PVA hydrogel dressing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911362307.5A CN110917391A (en) | 2019-12-26 | 2019-12-26 | Polypeptide modified sodium alginate/PVA hydrogel dressing and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911362307.5A CN110917391A (en) | 2019-12-26 | 2019-12-26 | Polypeptide modified sodium alginate/PVA hydrogel dressing and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110917391A true CN110917391A (en) | 2020-03-27 |
Family
ID=69862131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911362307.5A Pending CN110917391A (en) | 2019-12-26 | 2019-12-26 | Polypeptide modified sodium alginate/PVA hydrogel dressing and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110917391A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114425098A (en) * | 2022-02-08 | 2022-05-03 | 褚二喜 | Antibacterial and anti-inflammatory medical gel and preparation method thereof |
| CN114796620A (en) * | 2022-04-24 | 2022-07-29 | 广东顺德工业设计研究院(广东顺德创新设计研究院) | Interpenetrating network hydrogel used as medical implant material and preparation method and application thereof |
| CN115634314A (en) * | 2022-10-28 | 2023-01-24 | 广州贝奥吉因生物科技股份有限公司 | Non-supported bone repair gel microsphere and preparation method thereof |
| CN118806980A (en) * | 2024-09-18 | 2024-10-22 | 吉林省海卓生物科技有限公司 | Antibacterial modified sodium alginate aerogel hemostatic dressing and preparation method thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101426530A (en) * | 2004-05-12 | 2009-05-06 | 梅迪沃什有限公司 | Wound healing polymer compositions and methods for use thereof |
| US20100285094A1 (en) * | 2006-04-20 | 2010-11-11 | University Of Utah Research Foundation | Polymeric compositions and methods of making and using thereof |
| CN102078636A (en) * | 2011-01-07 | 2011-06-01 | 中山大学孙逸仙纪念医院 | Hydrogel dressing containing recombinant human epidermal growth factor and preparation method and application thereof |
| CN106390185A (en) * | 2016-12-02 | 2017-02-15 | 上海其胜生物制剂有限公司 | Preparation method of biological mimetic tissue adhesive |
| CN106512064A (en) * | 2017-01-12 | 2017-03-22 | 广东泰宝医疗器械技术研究院有限公司 | Skin wound dressing with antimicrobial property and preparation method of skin wound dressing |
| CN109260508A (en) * | 2018-08-08 | 2019-01-25 | 华南理工大学 | A kind of polyvinyl alcohol/Sodium Alginate Hydrogel Films preparation method with promotion skin fibroblasts proliferative functionality |
| CN109503864A (en) * | 2018-12-04 | 2019-03-22 | 上海其胜生物制剂有限公司 | One kind has the preparation method of the injection aquagel of cohesion enhancing characteristic |
| CN109701069A (en) * | 2019-01-29 | 2019-05-03 | 北京化工大学 | A kind of antibacterial tissue adhesive and preparation method thereof |
| CN109731130A (en) * | 2018-11-14 | 2019-05-10 | 华中科技大学同济医学院附属协和医院 | A method for preparing hydrogel wound dressings by low-temperature bio-3D printing technology |
-
2019
- 2019-12-26 CN CN201911362307.5A patent/CN110917391A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101426530A (en) * | 2004-05-12 | 2009-05-06 | 梅迪沃什有限公司 | Wound healing polymer compositions and methods for use thereof |
| US20100285094A1 (en) * | 2006-04-20 | 2010-11-11 | University Of Utah Research Foundation | Polymeric compositions and methods of making and using thereof |
| CN102078636A (en) * | 2011-01-07 | 2011-06-01 | 中山大学孙逸仙纪念医院 | Hydrogel dressing containing recombinant human epidermal growth factor and preparation method and application thereof |
| CN106390185A (en) * | 2016-12-02 | 2017-02-15 | 上海其胜生物制剂有限公司 | Preparation method of biological mimetic tissue adhesive |
| CN106512064A (en) * | 2017-01-12 | 2017-03-22 | 广东泰宝医疗器械技术研究院有限公司 | Skin wound dressing with antimicrobial property and preparation method of skin wound dressing |
| CN109260508A (en) * | 2018-08-08 | 2019-01-25 | 华南理工大学 | A kind of polyvinyl alcohol/Sodium Alginate Hydrogel Films preparation method with promotion skin fibroblasts proliferative functionality |
| CN109731130A (en) * | 2018-11-14 | 2019-05-10 | 华中科技大学同济医学院附属协和医院 | A method for preparing hydrogel wound dressings by low-temperature bio-3D printing technology |
| CN109503864A (en) * | 2018-12-04 | 2019-03-22 | 上海其胜生物制剂有限公司 | One kind has the preparation method of the injection aquagel of cohesion enhancing characteristic |
| CN109701069A (en) * | 2019-01-29 | 2019-05-03 | 北京化工大学 | A kind of antibacterial tissue adhesive and preparation method thereof |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114425098A (en) * | 2022-02-08 | 2022-05-03 | 褚二喜 | Antibacterial and anti-inflammatory medical gel and preparation method thereof |
| CN114796620A (en) * | 2022-04-24 | 2022-07-29 | 广东顺德工业设计研究院(广东顺德创新设计研究院) | Interpenetrating network hydrogel used as medical implant material and preparation method and application thereof |
| CN114796620B (en) * | 2022-04-24 | 2023-09-29 | 广东顺德工业设计研究院(广东顺德创新设计研究院) | An interpenetrating network hydrogel used as a medical implant material and its preparation method and application |
| CN115634314A (en) * | 2022-10-28 | 2023-01-24 | 广州贝奥吉因生物科技股份有限公司 | Non-supported bone repair gel microsphere and preparation method thereof |
| CN115634314B (en) * | 2022-10-28 | 2023-08-04 | 广州贝奥吉因生物科技股份有限公司 | Unsupported bone repair gel microsphere and preparation method thereof |
| CN118806980A (en) * | 2024-09-18 | 2024-10-22 | 吉林省海卓生物科技有限公司 | Antibacterial modified sodium alginate aerogel hemostatic dressing and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110917392B (en) | Hemostatic and antibacterial hydrogel with adhesiveness and preparation method thereof | |
| CN111675789B (en) | Polydopamine-heparin/quaternary ammonium salt/polyacrylamide hydrogel and preparation | |
| Lu et al. | A novel in situ‐formed hydrogel wound dressing by the photocross‐linking of a chitosan derivative | |
| CN110917391A (en) | Polypeptide modified sodium alginate/PVA hydrogel dressing and preparation method thereof | |
| CN111154149A (en) | A kind of hydrogel and its preparation method and dressing | |
| WO2023231050A1 (en) | Tough antibacterial hydrogel dressing and preparation method therefor | |
| CN106512064B (en) | skin wound dressing with antibacterial performance and preparation method thereof | |
| CN108484936B (en) | Hydrogel prepared from graft modified material and preparation method and application thereof | |
| CN112876694A (en) | Preparation method and application of acrylic acid/epsilon-polylysine adhesive antibacterial hydrogel | |
| CN111166931A (en) | Methacrylic acid sericin/chitosan quaternary ammonium salt hydrogel and preparation method and application thereof | |
| CN113509591A (en) | Antibacterial cationic injectable hydrogel dressing and preparation method thereof | |
| CN112675353A (en) | Recombinant collagen dressing and preparation method thereof | |
| US4778825A (en) | Macrophage stimulation by quadrol | |
| CN118718076A (en) | A nanocomposite hydrogel dressing and preparation method thereof | |
| CN112587726B (en) | Composite hydrogel stent and preparation method and application thereof | |
| CN112472867A (en) | Antibacterial medical hydrogel dressing and preparation method thereof | |
| CN116099038A (en) | Bioactive hydrogel and preparation method thereof | |
| CN110960722A (en) | Antibacterial alginate bandage and preparation method thereof | |
| CN119754018B (en) | A composite fiber antibacterial bandage and preparation method thereof | |
| CN113209361B (en) | Biological material composite hydrogel wound dressing and preparation method thereof | |
| CN120037453A (en) | Antibacterial and antioxidant bionic hydrogel, preparation method and application | |
| CN119139537A (en) | Sodium alginate hydrogel dressing with high water absorption rate and application | |
| CN112007201A (en) | Adhesive antibacterial hemostatic sponge and preparation method thereof | |
| CN115558128B (en) | A hydrogel dressing with peroxidase activity and its preparation method and application | |
| CN110507846B (en) | A kind of preparation method of long-acting antibacterial and healing-promoting keratin dressing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200327 |